NDAORALTABLET
Approved
Oct 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
DAYPRO (oxaprozin) by Pfizer is cyclooxygenase inhibitors [moa]. First approved in 1992.
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DAYPRO (oxaprozin) is an oral nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain. It is indicated for rheumatoid arthritis, osteoarthritis, and other inflammatory conditions. The drug works by blocking prostaglandin synthesis, a key inflammatory pathway.
$0.035BPart D
LOE ApproachingDeclining
As a mature product approaching loss of exclusivity, the DAYPRO team is likely smaller and focused on defending market share against generic competition rather than growth initiatives.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Drug-drug Interaction Study of FYU-981 and Oxaprozin
Started Nov 2017
12 enrolled
Healthy
Career Relevance
Working on DAYPRO offers limited growth trajectory but stable, predictable commercial responsibilities focused on contract management, generic defense, and customer retention in a declining market. This role suits professionals seeking mature portfolio experience rather than launch or innovation-driven careers.
Brand Manager
Worked on DAYPRO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.